Capsyd is an early-stage biotech company focused on the discovery and development of phage-based antibacterial treatments. Our mission is to address the looming superbug crisis by bringing safe and effective antibacterials to market, with special attention to cost-efficiency, global access, and sustainability.

​

With proprietary technology and an interdisciplinary team, we are building a library of engineered phages that addresses the current challenges in the development of phage therapeutics, the future of antibacterial treatment. Today, Capsyd's job is to develop a bioengineered phage cocktail against Clostridium difficile (C-Diff) infections, the number one healthcare-associated infection in the United States.

​

​